Novo Nordisk Seeks To Halt Sanofi Insulin Pen

Law360, New York (September 12, 2007, 12:00 AM EDT) -- Novo Nordisk A/S is asking a New Jersey federal court to stop Sanofi-Aventis sales of recently launched insulin pen SoloStar.

Novo Nordisk filed a motion for a preliminary injunction on Monday that would prevent Sanofi-Aventis and its U.S. affiliate from making and selling SoloStar in the U.S. until the conclusion of its patent infringement case.

Denmark-based drug-maker Novo says SoloStar is threatening its market share for pens and long-lasting insulin.

“Prompt resolution of Novo’s motion for preliminary injunction is essential here because the importation, sale, and...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.